Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 29:10:974049.
doi: 10.3389/fped.2022.974049. eCollection 2022.

Stability of novel urinary biomarkers used for lupus nephritis

Ellen M Cody  1 , James E Rose  1 , Bin Huang  1   2   3 , Tingting Qiu  1   2 , Hermine I Brunner  1   3   4 , Prasad Devarajan  1   3
Affiliations

Stability of novel urinary biomarkers used for lupus nephritis

Ellen M Cody et al. Front Pediatr. .

Abstract

Background: The Renal Activity Index for Lupus (RAIL) is a composite score of six urinary biomarkers (neutrophil gelatinase-associated lipocalin (NGAL), monocyte chemoattractant protein-1 (MCP-1), kidney injury molecule-1 (KIM-1), ceruloplasmin, adiponectin, and hemopexin) used to monitor lupus nephritis activity in children. We tested stability of RAIL biomarkers prior to meaningful clinical use.

Methods: Urine samples were tested by ELISA under shipping conditions, freeze/thaw, ambient and longer-term storage. Statistical analysis was performed via Deming Regression, Bland-Altman and Spearman Correlation Coefficient.

Results: Biomarker concentration were comparable to freshly collected urine following storage at -80 °C for up to 3 months, and at 4 or 25 °C up to 48 h followed by -80 °C. Neither shipping on dry or wet ice exposure nor addition of two freeze-thaw cycles led to loss of signal, with excellent Spearman Correlation coefficients under all conditions.

Conclusions: RAIL biomarkers are stable following short-term storage at clinically relevant conditions.

Keywords: SLE; biomarker; lupus nephritis; stability; urine.

PubMed Disclaimer

Conflict of interest statement

Author PD is a co-inventor on submitted patents for the use of NGAL as a biomarker of kidney disease. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of the 10 experimental conditions per urine sample. Image made with BioRender.
Figure 2
Figure 2
Adiponectin Bland-Altman charts by experimental condition. Image made with BioRender.
Figure 3
Figure 3
Ceruloplasmin Bland-Altman charts by experimental condition. Image made with BioRender.
Figure 4
Figure 4
Hemopexin Bland-Altman charts by experimental condition. Image made with BioRender.
Figure 5
Figure 5
MCP-1 Bland-Altman charts by experimental condition. Image made with BioRender.
See this image and copyright information in PMC

References

    1. Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis. (2020) 76:265–81. 10.1053/j.ajkd.2019.10.017 - DOI - PubMed
    1. Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. (2017) 12:825–35. 10.2215/CJN.05780616 - DOI - PMC - PubMed
    1. Silva CA, Avcin T, Brunner HI. Taxonomy for systemic lupus erythematosus with onset before adulthood. Arthritis Care Res. (2012) 64:1787–93. 10.1002/acr.21757 - DOI - PMC - PubMed
    1. Aggarwal A, Srivastava P. Childhood onset systemic lupus erythematosus: how is it different from adult SLE? Int J Rheum Dis. (2015) 18:182–91. 10.1111/1756-185X.12419 - DOI - PubMed
    1. Borgia RE, Silverman ED. Childhood-onset systemic lupus erythematosus: an update. Curr Opin Rheumatol. (2015) 27:483–92. 10.1097/BOR.0000000000000208 - DOI - PubMed